Press Releases

At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International, a global contract research, development and manufacturing organization (CRDMO), will announce that its newly upgraded biologics facility - Unit 3 - would be operational for clinical and commercial supply in the second half of 2024. The facility will be available for biotech and pharma customers seeking drug substance and drug product contract manufacturing.  The drug substance capacity includes t

Viroclinics-DDL (referred to herein as Cerba Research, the Netherlands) a world leading vaccine and antiviral specialty laboratory providing research and clinical trial solutions rooted in virology, proudly announces changing its name to Cerba Research as of the 1st of April 2024. This branding step was an expected move after the Viroclinics-DDL teams had joined Cerba Research in 2022, now operating as one company well positioned in the entire value chain of research and clinical trials.

ProBioGen, a leading CDMO of innovative solutions and services for biopharmaceutical development, is pleased to announce the execution of services and license agreements with MAPP BIOPHARMACEUTICAL, INC. to develop a cell line for an afucosylated antibody targeting Marburg virus (MARV) infection. This collaborative effort will leverage ProBioGen's cutting-edge GlymaxX® technology to enhance the therapeutic potential of the antibody by adjusting the afucosylation levels. Unde

ProteoNic Biosciences, a leading provider of premium vector technology and services for the production of biologics, today announced a partnership with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity. This strategic alliance will grant Ginkgo Bioworks’ customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for cell and gene therapy applications. Thi

Expert Systems, a leader in AI-enabled drug discovery, announces the expansion of the collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program, which Eilean has recently acquired from Ness Therapeutics Inc (Ness) in an all-equity transaction. "Eilean's lead PTPN2 inhibitor molecules demonstrate exceptional efficacy, selectivity, oral bioavailability and a good safety profile," commended Bill Farley, CBO at Expert Systems. "We're proud

Replay, a genome writing company reprogramming biology by writing, designing, and delivering big DNA, today announced that the first patient has been dosed in the Phase 1/2 study of NY-ESO-1 TCR/IL-15 NK, an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for relapsed or refractory multiple myeloma. NY-ESO-1 TCR/IL-15 NK is being developed by Syena, an oncology-focused product company launched by Replay and The University of Texas MD Anderson Cancer Center,, based on

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader-based medicines, today announced a novel development candidate, MRT-8102, a potent, highly selective and orally bioavailable NIMA related kinase 7 (NEK7)-directed MGD. MRT-8102 is expected to be developed for the treatment of inflammatory diseases driven by interleukin-1β (IL-1β) and the NLRP3 inflammasome, which are critical elements of the inflammatory process. This is th

ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of the Phase 1 clinical trial for IM-101. IM- 101 is a humanized monoclonal antibody that targets complement C5, which plays a central role in complement activation. The crucial role of the complement system in autoimmune diseases is well known. The randomized, double-blind, placebo-controlled study was conducted to evaluate the safety

SciSparc Ltd, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the first patient has been enrolled in the Company's clinical trial assessing the efficacy and safety of SCI-210 for the treatment of children with autism spectrum disorder (“ASD”) between the ages of 5 and 18. Autism, also referred to as autism spectrum disorder, is one of the most common deve

Galimedix Therapeutics, Inc, a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, announces encouraging data with orally available small molecule GAL-201, showing its neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD). These new findings strongly support previous studies where GAL-201 was characterized as a pr